Conditioning Regimens in Long-Term Pre-Clinical Studies to Support Development of Ex Vivo Gene Therapy: Review of Nonproliferative and Proliferative Changes

Hum Gene Ther. 2021 Jan;32(1-2):66-76. doi: 10.1089/hum.2020.135. Epub 2020 Oct 15.

Abstract

Hematopoietic stem cell gene therapy has become a successful therapeutic strategy for some inherited genetic disorders. Pre-clinical toxicity studies performed to support the human clinical trials using viral-mediated gene transfer and autologous hematopoietic stem and progenitor cell (HSPC) transplantation are complex and the use of mouse models of human diseases makes interpretation of the results challenging. In addition, they rely on the use of conditioning agents that must induce enough myeloablation to allow engraftment of transduced and transplanted HSPC. Busulfan and total body irradiation (TBI) are the most commonly used conditioning regimens in the mouse. Lenticular degeneration and atrophy of reproductive organs are expected histopathological changes. Proliferative and nonproliferative lesions can be observed with different incidence and distribution across strains and mouse models of diseases. The occurrence of these lesions can interfere with the interpretation of pre-clinical toxicity and tumorigenicity studies performed to support the human clinical studies. As such, it is important to be aware of the background incidence of lesions induced by different conditioning regimens. We review the histopathology results from seven long-term studies, five using TBI and two using busulfan.

Keywords: busulfan; gene therapy; hematopoietic system; lymphoma; mouse model; radiation.

Publication types

  • Review

MeSH terms

  • Animals
  • Busulfan
  • Cyclophosphamide
  • Genetic Therapy
  • Hematopoietic Stem Cell Transplantation*
  • Mice
  • Transplantation Conditioning*
  • Whole-Body Irradiation

Substances

  • Cyclophosphamide
  • Busulfan